SINGAPORE (Reuters) – Singapore has approved Pfizer’s oral COVID-19 medicine Paxlovid, its Health Sciences Authority (HSA) said on Thursday.
Paxlovid is the first COVID-19 oral treatment authorised for use in the city-state for the treatment of mild to moderate cases among adults at high risk of severe disease, HSA said in a statement.
(Reporting by Chen Lin; Editing by Martin Petty)
